MEDA Receives FDA Approval of New ASTEPRO Nasal Spray
Wed, 09/02/2009 - 4:37am
Meda Pharmaceuticals Inc. hasannounced that the FDA has approved ASTEPRO(azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms ofseasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO NasalSpray 0.15% is the first nasal antihistamine to offer convenient once-dailydosing for patients who suffer from seasonal allergies. ASTEPRO Nasal Spray0.15% relieves rhinitis symptoms, including nasal congestion, without an addeddecongestant such as pseudoephedrine and is formulated with azelastine, aleading nasal antihistamine in the treatment of seasonal rhinitis in the U.S.The product will be available in pharmacies in early October.